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Objectives: To evaluate possible lipid catabolism and body fat regulation effects of 3-
caffeoylquinic acid in Green coffee bean extract (GCBE) in high-fat diet (HFD)-
induced obese mice.
Methods: Obesity was induced in mice using a HFD for four weeks. Then, mice were
fed only HFD or HFD with GCBE at 50, 100, and 200 mg/kg. Fatty acid synthesis
mechanism regulation of body fat was investigated through real-time PCR and Western
blot assay. Body fat reduction was measured through dual-energy X-ray absorptiometry.
Results: In HFD-induced obese mice, GCBE treatment signiﬁcantly decreased body
weight gain, liver weight and white adipose tissue weights with regulation of adipose
tissue lipolysis hormones, like adiponectin and leptin. GCBE treatment decreased mRNA
expression levels of adipogenesis and adipocyte metabolism related genes in adipose
tissues and the liver, and decreased the corresponding protein expression. Dual energy X-
ray absorptiometry measurements were used to compare body fat between mice on high-
fat and those treated with GCBE. GCBE treated mice had a lower fat mass compared to
HFD alone fed mice and relative body weight and fat mass were markedly decreased.
Conclusions: GCBE has a potential anti-obesity effect with lowering body fat accu-
mulation by regulating adipogenesis and lipid metabolism-related genes and proteins in
WAT and liver.1. Introduction
In recent decades, obesity has become a serious clinical
disease that is contributed by a high-fat diet. The World Health
Organization deﬁnes obesity was abnormal or excessive fat
accumulation is present in many diseases. Another deﬁnition of
obesity is the accumulation of body fat from the imbalancebetween calorie input and energy expenditure. Incremental evi-
dence suggests obesity is related to epidemiological diseases
including diabetes, heart disease, stroke, arthritis, inﬂammation,
and cancers [1]. Therefore, the role of fat in obesity development
is important to study to prevent and treat obesity. Adipocytes
store energy in triglyceride form and break down lipids into
free fatty acids when energy is required [2]. Furthermore,
adipocytes play a major role in obesity and related disease
through the secretion of wide range of regulatory factors.
Remarkably, adipocytes hormonally control metabolism
through the secretion of autocrine, paracrine, and endocrine
hormones and effect insulin sensitivity, immune function,
eating behavior, and most importantly regulate differentiation
of preadipocytes into adipocytes [3].
Polyphenols are abundant secondary metabolites in plants
and are known to prevent diseases associated with oxidative
stress and its related complications. The glycosylated derivate
forms of polyphenol, chlorogenic acids (CGA) (ester of caffeicticle under the CC BY-NC-ND license (http://
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is an increase in scientiﬁc evidence that coffee affects metabolic
syndromes such as obesity, type 2 diabetes, atherosclerosis, and
insulin-resistance [5–9].
Green coffee is raw coffee beans that have not been roasted.
Many different pharmacological studies about green coffee bean
extract (GCBE) demonstrates that the CGA in green coffee
regulates hypertensive, vasoreactivity, and glucose metabolism
[10–12]. There are several prospective studies regarding how 5-
caffeoylquinic acid (5-CQA), the major chlorogenic acid in
coffee, decreases diabetes risk by decreasing glucose uptake in
the small intestine. However, only the short-term effects were
analyzed and more research is needed [7,13]. In particular, recent
studies propose that attenuation of obesity and lipid
accumulation by green coffee bean extract is derived from 5-
CQA in diet-induced obesity and insulin resistance [14,15].
In the present study, we investigate a quantitative analysis of
the 3-caffeoylquinic acid (3-CQA) in GCBE and examined
whether it has an ameliorative effect against high-fat diet (HFD,
60% calories from fat) induced obesity in mice. Furthermore,
decreases in lipid accumulation and metabolism related genes,
proteins, and body fat composition provide scientiﬁc evidence to
support GCBE as a supplement to prevent obesity.
2. Materials and methods
2.1. Chemicals and reagents
Isopropanol, TRI reagent and protease inhibitor cocktail were
purchased from Sigma–Aldrich (MO, USA). HPLC grade
acetonitrile and phosphoric acid were purchased from Merck
(Darmstadt, Germany). Polyclonal antibodies against FAS,
SREBP-1c, PPARg, C/EBPa, AMPK, phospho-AMPK, PPARa
and b-actin were purchased from Santa Cruz Biotechnology
(CA, USA). Horseradish peroxidase-linked anti rabbit IgG and
HRP-linked anti mouse IgG were purchased from Bio-Rad (CA,
USA). SYBR Green reaction buffer was purchased from Takara
(Shiga, Japan).
2.2. Compound analysis of GCBE
GCBE was provided from KPLC group (Montagne, France).
Chromatographic analysis of 3-CQA in GCBE was performed
using the Agilent 1260 HPLC system (Agilent Technologies,
Santa Clara, CA, USA) with a UV detector. The C18 column
(5 mm, 4.6 × 250 mm; Supelco, MO, USA) was maintained at
40 C for chromatographic separation. The mobile phase was
mixture of 0.5% phosphoric acid in distilled water (A) and 0.5%
phosphoric acid in acetonitrile (B) and delivered at 1.2 mL/min
in a gradient ﬂow as follows: 0 min 8.0%, followed by 20 min
25.0%, 35 min 100.0%, and 45 min 8%. The injected volume
was 5.0 mL and optimal detection was achieved at 325 nm. The
standard samples for 3-CQA was purchased from Sigma Aldrich
(MO, USA) and freshly prepared for analysis.
2.3. Animal studies
Male C57BL/6J mice were obtained from DaeHan BioLink
(Chungbuk, South Korea) at four weeks of age. The mice were
individually housed in stainless steel cages and were maintained
under temperature of (23 ± 3) C in a humidity-controlled roomwith a 12–12 h light–dark cycle. Allmicewere given free access to
water and food. After acclimatization for one week, they were fed
either the normal-fat diet (NFD, n = 8, certiﬁed irradiated global
18% protein diet, 2918C, Harlan Laboratories, Indiana, USA) or
High-fat diet (HFD, n = 40, Rodent diet with 60% Kcal from Fat,
#101556; Research Diets, USA) for four weeks to induce obesity.
After obesity induction, the mice were divided into ﬁve experi-
mental groups (n = 8/group) and were matched by body weight.
The following ﬁve groups were studied for six weeks:
normal-fat diet, HFD, and HFD with oral administration of
GCBE at 50 mg/kg of body weight (HFD + GCBE 50); HFD
with GCBE at 100 mg/kg of body weight (HFD + GCBE 100);
HFD with GCBE at 200 mg/kg of body weight (HFD + GCBE
200). Food intake of the mice was recorded daily and their body
weights were measured twice per week. At the end of the
experiment, the mice were anesthetized and the liver, kidney,
and white adipose tissue (WAT) were excised immediately.
Each tissue was then rinsed with phosphate-buffered saline, and
stored at −80 C until analysis. The experimental procedures
were approved by Ethics Committee of the Wonkwang Uni-
versity (Iksan, Korea) and the mice were maintained in accor-
dance with their guidelines.
2.4. Plasma biochemical analysis
After six weeks of feeding, 12 h fasted mice were anes-
thetized using ether and blood was collected. Collected samples
were centrifuged at 2500×g for 15 min at 4 C for biochemical
analyses of plasma parameters. The separated plasma was stored
at −80 C until analysis. The levels of serum glucose, total
cholesterol (T-CHO), triglyceride (TG), low-density lipoprotein-
cholesterol (LDL-C), high-density lipoprotein-cholesterol
(HDL-C), Alanine transaminase (ALT), Aspartate transaminase
(AST), free fatty acid (FFA), leptin, and adiponectin were
measured using commercial kits (Sigma–Aldrich, MO, USA)
according to the manufacturer's instructions.
2.5. Histological analysis
Liver and adipose tissue were dissected, ﬁxed in 10% neutral
buffered formalin, and embedded in parafﬁn for histological
examination. The formalin-ﬁxed and parafﬁn-embedded tissue
blocks were cut to a thickness of 4 mm and stained with he-
matoxylin and eosin (H&E). The sections were photographed
under 200× magniﬁcation.
2.6. Protein extraction and Western blot analysis
Cold phosphate-buffered saline washed adipose and liver
tissues were homogenized in RIPA buffer (50 mM Tris–HCl pH
7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium
deoxycholate, 0.1% SDS, 1 mM PMSE) and 1% protease in-
hibitor cocktail. The homogenates were centrifuged 8000×g for
15 min at 4 C and the supernatants were collected. Total protein
concentration was calculated by BCA protein assay (Pierce, IL,
USA). Proteins were separated on 10% sodium dodecyl sulfate
polyacrylamide (SDS-PAGE) gels and transferred to poly-
vinylidene diﬂuoride membranes (Bio-Rad Laboratories, Her-
cules, CA, USA). The membranes were blocked with 5% non-
fat skim milk in Tris-buffered saline containing 0.1% Tween
20 (TBS-T) and were incubated overnight at 4 C with
Figure 1. Representative HPLC chromatograms of 3-CQA (A) in GCBE
(B) measured at a wavelength of 325 nm.
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membranes were washed with TBS-T and then incubated with
anti-mouse or anti-rabbit horseradish peroxidase-conjugated
secondary antibodies for 1 h. After washing, the immunocom-
plexes were visualized by chemiluminescence reagents and
detected by chemi-luminometer (CLINX Science Instruments
Co. Ltd., Shanghai, China).
2.7. Isolation of total RNA and quantitative real-time
PCR
Total RNA of adipose and liver tissues was isolated using the
RNeasy mini kit (Qiagen, Velno, Netherlands) according to the
manufacturer's protocol. The extracted RNA was reverse tran-
scribed to cDNA by using Primescript ﬁrst strand cDNA syn-
thesis kit (Promega, Fitchburg, USA). Then the RNA expression
levels of adipogenesis, beta-oxidation, and lipolysis related
genes were analyzed by a real-time PCR LightCycler 96 system
(Roche, Basel, Switzerland) using a SYBR Green Master PCR
Kit (Takara, Shiga, Japan) according to the manufacturer's
protocols. Primer sequences were as follows (forward and
reverse, respectively): b-actin, TGT CCA CCT TCC AGC AGA
TGT and AGC TCA GTA ACA GTC CGC CTA GA; Peroxi-
some proliferator-activated receptor a (PPARa), CAG CGA
GTA GCG CAT AGT CA and GGA TGT CAC ACA CAA
TTC; PPARg; TCA CAA GAG GTG ACC CAA TG and CCA
TCC TTC ACA AGC ATG AA; Adiponectin, GCA CTG GCA
AGT TCT ACT GCA A and GTA GGT GAA GAG AAC GGC
CTT GT; Adipose triglyceride lipase (ATGL), AAC ACC AGC
ATC CAG TTC AA and GGT TCA GTA GGC CAT TCC TC;
Hormone-sensitive lipase (HSL), ACC GAG ACA GGC CTC
AGT GTG and GAA TCG GCC ACC GGT AAA GAG; Sterol
regulatory element binding protein-1c (SREBP-1c), GGC ACT
AAG TGC CCT CAA CCT and GCCACA TAG ATC TCT
GCC AGT GT; SREBP-2, GGC ACT AAG TGC CCT CAA
CCT and CAC CAT TTA CCA GCC ACA GG; Carnitine
palmitoyl transferase-1 (CPT-1), AAA GAT CAA TVG GAC
CCT AGA and CAG CGA GTA GCC CAT AGT CA; and
CCAAT/enhancer-binding protein a (C/EBPa), GTG TGC
ACG TCT ATG CTA AAC and GCC GTT AGT GAA GAG
TCT CAG. The real-time PCR cycling conditions were as fol-
lows: 2 min at 95 C; 45 cycles of 20 s at 95 C, 20 s at 60 C,
40 s at 72 C, and 30 s at 72 C; and a ﬁnal extension for
5 min at 72 C followed by a melting curve analysis. The mRNA
levels of the target genes were normalized to the expression level
of b-actin and the results were presented as the fold changes
relative to the HFD group.
2.8. Body fat composition analysis
Dual energy X-ray Absorptiometry (DXA) measurements
were used to compare body fat between C57BL6J mice on HFD
and treated with GCBE. DXA measurements were performed
after six weeks of administration using a total-body scanner
(InAlyzer dual X-ray absorptiometry, Medikors, Gyeonggi,
Korea). DXA measures one time with low energy and one time
with high energy to separate the images into bones and tissues in
gram units by separating them into fat and lean before analysis.
Radiography of body fat was displayed by three modes ac-
cording to low density fat (blue color), medium density fat
(yellow color) and high density fat (red color).2.9. Statistical analysis
Statistical evaluations of the data were expressed as the
mean ± SEM. The statistical signiﬁcance of the differences be-
tween the mean values for the treatment groups was analyzed by
Student's t-tests and one-way analysis of variance (ANOVA)
using the software, Origin 7 (Microcal Software, USA). Values
of P < 0.05 and P < 0.01 were considered statistically
signiﬁcant.
3. Results
3.1. CQA composition in GCBE
To determine the composition of 3-CQA in GCBE, we
compared the chromatographic proﬁles of a standard on HPLC
analysis (Figure 1). Total CQA content in the GCBE was 50%
and the 3-CQA composition in the GCBE was approximately
27.5% and was conﬁrmed by comparing the chromatogram of
the standard. The optimized green coffee bean was used in all
subsequent experiments.
3.2. Effects of GCBE on food intake and body weight
gain
We elucidated the effects of GCBE supplementation on HFD
induced obese mice. Food intake and body weight gain were
compared with those of mice fed normal diet, HFD, and HFD
with GCBE (Figure 2). The initial body weights were not
different among the groups. The body weight gain in HFD
groups was higher than in the normal diet group. Whereas, the
body weight of HFD with GCBE at 100 and 200 mg/kg were
observed to signiﬁcantly decrease body weight gain compared to
the HFD group (P < 0.05 and P < 0.01, respectively).
3.3. Effects of GCBE on organ and white adipose tissue
weights
The effects of GCBE on the relative weight of liver, peri-
renal, retroperitoneal, and epididymal WAT were compared to
Figure 2. Effects of GCBE on body weight gain and food intake rate in
HFD-induced obese mice for six weeks. (A) Food intake rate. (B) Body
weight gain.
*P < 0.05 and **P < 0.01 compared to the HFD group (n = 8 per group).
Figure 3. Effects of GCBE on organ weight in mice fed a HFD for six
weeks.
*P < 0.05 and **P < 0.01 compared to the HFD group (n = 8 per group).
Bong-Keun Choi et al./Asian Paciﬁc Journal of Tropical Medicine 2016; 9(7): 635–643638the HFD group (Figure 3). The organ weights from mice in the
HFD group were higher than in the normal diet group. However,
the HFD with GCBE group showed a decreased liver, perirenal,
retroperitoneal, epididymal, and total WAT weights. However,
the relative organ weights in the HFD + GCBE 200 group
exhibited a signiﬁcant reduction compared to the HFD group
(P < 0.05).
3.4. Effects of GCBE on plasma biochemical parameters
Table 1 shows the effects of GCBE on the plasma
biochemical parameters. In the plasma biochemical analysis
glucose, T-CHO, TG, LDL-C, HDL-C, ALT, AST, and leptin
levels in the normal diet group were signiﬁcantly lower than in
the HFD group (all, P < 0.01). Analysis of lipid levels in the
HFD + GCBE 200 group had signiﬁcantly reduced plasma T-
CHO, TG, and LDL-C levels (all, P < 0.01), whereas HDL-C
levels in HFD with GCBE groups increased when compared
to the HFD group. ALT, AST, and FFA were signiﬁcantly
reduced in the HFD with GCBE 100 and 200 groups when
compared to the normal diet group (all, P < 0.01). The con-
centration of leptin in the HFD with GCBE 100 and 200 groups
displayed a statistically signiﬁcant reduction compared to the
HFD group (P < 0.05 and P < 0.01, respectively). However, the
adiponectin levels in mice fed GCBE showed signiﬁcant in-
creases (P < 0.05).3.5. Effects of GCBE on liver and epididymal adipose
tissue morphology
Figure 4 shows microphotographic observations of hepatic
tissues and epididymal adipose tissue sections by hematoxin and
eosin (H&E) staining. Experimental mice in the ﬁgure are as
follows: Normal diet, HFD, HFD with 50 mg/kg, HFD with
100 mg/kg, and HFD with 200 mg/kg groups. In the case of the
liver, large macrovascular adipocyte were found in the HFD
group when compared to the normal diet group. However, the
HFD with GCBE 50, 100, and 200 mg/kg groups showed
markedly reduced hepatic steatosis compared to the HFD
induced group (Figure 4A).
Lipid accumulation and cellular morphology in epididymal
WAT was examined by H&E staining. The adipocyte size in the
HFD group showed an increase compared to the normal diet
group. In the HFD with GCBE groups, we observed a marked
reduction of adipocyte hypertrophy compared to mice fed the
HFD alone (Figure 4B).
3.6. Effects of GCBE on mRNA expression of genes in
adipose tissues
We evaluated the effects of GCBE on the expression of
adipogenesis and adipocyte metabolism related genes by
Table 1
Effects of GCBE on plasma biochemical parameters in HFD-induced obese mice.
Parameters Normal HFD HFD + GCBE 50 HFD + GCBE 100 HFD + GCBE 200
Glucose (mg/dL) 121.00 ± 3.17** 181.25 ± 7.93 166.75 ± 7.70 142.30 ± 4.35** 169.00 ± 8.02
T-CHO (mg/dL) 77.87 ± 4.03** 179.75 ± 11.40 152.87 ± 8.40 145.75 ± 5.85* 141.00 ± 5.44**
TG (mg/dL) 83.62 ± 6.09** 103.12 ± 3.38 77.62 ± 4.09** 82.20 ± 3.35* 79.50 ± 2.80**
LDL-c (mg/dL) 3.87 ± 0.44** 36.90 ± 4.60 23.12 ± 3.28* 18.12 ± 2.68** 17.75 ± 2.66**
HDL-c (mg/dL) 84.37 ± 3.93** 140.50 ± 8.59 157.87 ± 6.31 145.87 ± 3.99 143.12 ± 3.77
ALT (U/L) 40.62 ± 1.99** 151.0 ± 13.34 62.42 ± 8.04** 65.33 ± 7.79** 55.28 ± 8.46**
AST (U/L) 155.25 ± 29.07** 252.60 ± 17.10 202.37 ± 11.00* 196.37 ± 13.96** 186.50 ± 10.37**
FFA (mEq/L) 1.42 ± 0.03 1.42 ± 0.03 1.10 ± 0.04** 0.98 ± 0.03** 1.04 ± 0.03**
Leptin (mg/mL) 1.60 ± 0.27** 53.94 ± 4.36 45.18 ± 6.04 42.77 ± 2.36* 29.40 ± 5.39**
Adiponectin (mg/mL) 12.07 ± 0.41** 9.46 ± 0.30 10.53 ± 0.51 11.30 ± 0.28* 11.89 ± 1.01*
*P < 0.05 and **P < 0.01, compared to the HFD group (n = 8 per group).
Figure 4. Histological observations of liver sections and epididymal adipose tissue.
(A) Liver and (B) epididymal adipose tissue were stained with hematoxylin and eosin, and were viewed under a microscope (×200). Representative sections
are from three mice from each treatment group.
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pose tissues using quantitative real-time PCR. As shown in
Figure 5, peroxisome PPARa, CPT-1, Adiponectin, ATGL, and
HSL mRNA expression levels in the HFD group were decreased
compared to the normal diet group. However, in the HFD with
GCBE groups, the mRNA levels of PPARa, Adiponectin,
ATGL, and HSL were signiﬁcantly upregulated in a dose-
dependent manner. In HFD plus GCBE 200 group,Figure 5. Effects of GCBE on genes expression levels in epididymal adipose
The mRNA expression levels of genes were evaluated by quantitative real-time
group).signiﬁcantly increased mRNA levels of ATGL and HSL,
whereas CPT-1 mRNA expression levels increased compared
with levels in adipose tissues of HFD group. The expression
levels of adipogenesis related genes displayed whether GCBE
affects adipose tissues of HFD group. C/EBPa, SREBP-1c and
PPARg were signiﬁcantly downregulated in the HFD with
GCBE 200 group compared with those in HFD group (P < 0.01
and P < 0.05, respectively).tissues.
PCR. *P < 0.05 and **P < 0.01 compared to the HFD group (n = 8 per
Bong-Keun Choi et al./Asian Paciﬁc Journal of Tropical Medicine 2016; 9(7): 635–6436403.7. Effects of GCBE on mRNA expression of genes and
proteins in the livers
To determine the mode of action of GCBE on HFD induced
obesity, we examined the mRNA and Protein expressions in the
liver. The adipogenesis and adipocyte metabolism related gene
expression levels in HFD with GCBE groups, we found that
PPARa, CPT-1, Adiponectin, ATGL, HSL, C/EBPa, SREBP-
1c, and PPARg were affected by GCBE in mice (Figure 6).
In the liver tissue, compared to the HFD group, mRNA
expression levels of the normal group displayed reductions in C/
EBPa, SREBP-1c, SREBP-2, and PPARg; and statistically
signiﬁcant increases in PPARa and CPT-1 (Figure 6A) (both,
P < 0.05). In the HFD with GCBE groups, PPARa mRNA
levels were signiﬁcantly upregulated (P < 0.05). The mRNA
expression levels of CPT-1 also showed a signiﬁcant increase in
a dose-dependent manner (P < 0.05). We found that in the HFD
with GCBE groups, the adipogenesis related genes C/EBPa,
SREBP-2, and PPARg expression levels also signiﬁcantly
decreased when compared to the mice fed HFD (Figure 6A). TheFigure 6. Effects of GCBE on gene expression levels and proteins in liver tis
(A) The mRNA expression levels of adipogenesis related genes were evaluated
were detected by Western blot analysis. *P < 0.05 and **P < 0.01, comparedtranscription factor SREBP-1c, a major lipogenic related protein,
was also signiﬁcantly reduced in HFD with GCBE groups
(Figure 6A). Figure 6B and C show protein expression levels
differences in GCBE supplemented groups. The target protein of
SREBP-1c, FAS was statistically signiﬁcantly reduced in the
GCBE 200 treated group compared with the HFD group.
Consistently, the C/EBPa protein expression level in the HFD
with GCBE groups was signiﬁcantly decreased in a dose-
dependent manner. Additionally, GCBE treatments decreased
protein expression of PPARg levels.
We also investigated the phosphorylation of AMPK and
PPARa protein expression. In the HFD group, pAMPK and
PPARa protein levels in the liver were markedly decreased
compared to the normal group. In contrast, GCBE 100 and 200
treatments signiﬁcantly increased pAMPK expression compared
to the HFD group (P < 0.01 and P < 0.05, respectively), similar
to the normal group. Interestingly, we observed that the PPARa
protein was markedly and dose dependently increased in the
mice fed HFD with GCBE groups, 5.6 times more than in the
HFD alone group (Figure 6C).sues.
by quantitative real-time PCR. (B) and (C) The protein expression levels
to the HFD group (n = 8 per group).
Figure 7. Distribution of fat mass and body weight measurements by DXA on mice fed a normal fat diet, high fat diet, and high fat diet with GCBE 100 mg/
kg.
(A) The radiography of body fat is displayed by three modes according to low density fat (blue), medium density fat (yellow), and high density fat (red). (B)
The body weight, and (C) fat mass were measured by DXA. *P < 0.05 and **P < 0.01 compared to the HFD group (n = 8 per group).
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measurements by DXA
To determine the effects of GCBE on HFD induced body
composition, fat mass and body weight were determined by
DXA. The DXA scan of the mice fed normal diet, HFD and
HFD with GCBE 200 mg/kg is presented as radiography of body
fat (Figure 7A). The HFD induced obese mice presented more
large red color area than blue and yellow, meaning they had
more high density of fat than low and medium density fats. The
GCBE supplement for six weeks signiﬁcantly reduced the body
weight in the HFD induced obese mice. Furthermore, the rela-
tive distribution of fat mass noticeably decreased (Figure 7B and
C) (P < 0.01).
4. Discussion
The chlorogenic acid was glycosylated derivate form of
polyphenol, caffeic and quinic acid combined form. Coffee has
high concentrations of chlorogenic acid as most common form is
5-CQA [1]. Previous studies have indicated that chlorogenic acid
has many potent biological properties [16–18]. Additionally,
recent reports of chlorogenic acid provide regulatory effects of
glucose and lipid concentrations in diabetes and obesity [19–22].
Song et al. [15] have reported that 5-CQA was the most
abundant and active compound in decaffeinated GCBE and has
weight lowering and insulin resistance effects in mice fed the
HFD at a dose of 300 mg/kg GCBE. Although previous reports
show the effects of GCBE on the development of obesity, theeffects of GCBE in HFD induced obese mice measuring total
body fat mass has not been investigated. Thus, our study pre-
sents that feeding 3-CQA rich GCBE ameliorates and suppresses
dietary-induced obesity and decreases body fat mass, directly.
Our data show that GCBE has anti-obesity effects and conﬁrms
previous studies. Further, we show that GCBE effects the
regulation of adipogenesis and lipid metabolism, directly
effecting the distribution of fat mass.
Increased fat intake leads to obesity with body weight gain
and glucose intolerant in mice [23]. We conﬁrmed that six weeks
of GCBE (Total chlorogenic acid was 50%, which was including
27.5% of 3-CQA) supplementation in a HFD did not affect the
food intake in HFD-induced obese mice. Additionally, body
weight gain in GCBE fed mice signiﬁcantly decreased compared
to mice fed a HFD alone. This phenomenon supports previous
reports that GCBE has anti-obesity effects [15].
Our results also show that GCBE supplementation signiﬁ-
cantly lowers plasma T-CHO, TG, FFA, and LDL-C levels
while increasing plasma HDL-C levels in the mice fed HFD.
These results suggest that GCBE could reduce HFD induced
hyperglycemia and hyperlipidemia.
Leptin and adiponectin regulate lipolysis through opposing
activities in adipocytes [24]. Mature adipocytes produce
adiponectin, which increases insulin sensitivity, glucose
uptake, fatty acid oxidation, and anti-inﬂammatory effects in
hormone-stimulated lipolysis [25]. To prevent lipid accumulation
in adipose tissue, adipocytes secrete leptin to regulate food
intake and fatty acid oxidation contacted with brain [26]. The
plasma concentration of adipose tissues and endocrine
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concentrations and inversely increased adiponectin, in a dose
dependent manner.
In addition, we conﬁrmed that mice fed GCBE showed sig-
niﬁcant decreases in liver and WAT weight in HFD-induced
obese mice. Moreover, in liver and adipocytes histological
analysis, GCBE treatment showed smaller adipocyte sizes and
number in the mice fed a HFD. These results indicate that GCBE
could decrease adipocytes, which demonstrates lipid accumula-
tion and un-oxidized fatty acid induces lipotoxicity and dysre-
gulation, which then decreases stimulation of lipolysis.
Another important ﬁnding in our study is that GCBE may
improve adipogenesis and lipid metabolism in HFD-induced
obese mice. Adipogenesis is the development of adipocyte dif-
ferentiation with the related gene transcription factors, C/EBPs
and PPARs [27]. In the mouse models, adipose tissue regulation
was related with PPARg and C/EBPa with HFD feeding. GCBE
treatment reduced C/EBPa, SREBP-1c, and PPARg mRNA
expression levels in expression [28,29]. PPARg expression is
activated in adipocytes genes [30]. The lipogenic transcription
factor, SREBP-1c, is a key regulator for fatty acid and choles-
terol, as well as, LDL receptor that activates lipogenesis [31].
To examine the underlying mechanisms, we induced obesity
with hyperglycemia and hyperlipidemia epididymal adipose
tissue. Additionally, we investigated lipid catabolism activity in
adipose tissues. Adipocytes have excess energy and store fatty
acids in the form of TG in lipid droplets. Consequently, energy
regulation of the catabolic pathway, including fatty acid oxida-
tion and glycolysis, is a strong candidate for obesity.
We also studied whether GCBE has anti-lipolytic effects in
adipocytes. PPARa is a nuclear receptor, which increases the
expression of gene CPT-1 to induce mitochondrial fatty acid to
dispose through b-oxidation [32]. GCBE treatment increases the
mRNA expression of PPARa and CPT-1, indicating GCBE
promotes energy dissipation in adipocyte tissues. The adipo-
nectin plasma concentration regulates lipid proﬁles. Gene
expression levels of adiponectin were also up-regulated by
GCBE treatment. HFD-induced obese mice presented a decrease
of adiponectin gene expression in adipose tissues [33]. Moreover,
Qiao et al. [25] proposed adiponectin inhibits lipolysis and
regulates lipid metabolism suppressing catabolites of TG by
inhibiting ATGL and HSL in mouse adipocytes. Our study
showed that lipolysis activity of GCBE was induced by
adiponectin, HSL, and ATGL mRNA expression in adipocyte
tissues. Based on these mRNA expression results in adipose
tissue, GCBE leads to reduced adipogenesis and lipid
accumulation in the adipose tissues of HFD-induced obese mice.
Of the adipogenesis-related gene and protein expression
levels in the liver, we found that the dose of GCBE treatment
signiﬁcantly up-regulated the lipid oxidation related genes, like
PPARa and CPT-1, and down-regulated the transcription factors
that regulate adipocyte differentiation, like C/EBPa, SREBPs,
and PPARg. There is a possibility GCBE treatment affects the
expression levels of adipogenesis-related genes and proteins. It
is likely that the anti-obesity effects of GCBE treatment are
caused by the suppression of gene expression and proteins
involved in fatty liver induced obesity.
In obesity development, AMPK is a key mediator that
switches adipocytes from anabolizing to catabolizing lipids. In
the liver, AMPK altered fatty acid oxidation and glycogenesis,
while switching off the synthesis of fatty acids, gluconeogenesis
and ATP consumption with PPARa [34,35]. In this study,phosphorylation of AMPK and PPARa increased in GCBE
treated groups in a dose dependent manner. From these
results, GCBE induced AMPK activation causes anabolic
stages involving fatty acid, glucose oxidation and inhibition of
adipocytes proliferation in obese mice.
Several epidemiologic studies have reported that body fat,
especially abdominal and visceral fat, in adiposity related
obesity is associated with increased risk of metabolic syndrome
[36]. Excess adiposity was measured using an imaging technique,
to investigate the fat tissue and fat distribution. DXA quantiﬁes
the past photon peaks through tissue-organs ex vivo with high
accuracy to understand the mechanisms involved in metabolic
regulation by measurement of fat distribution and composition
[37,38]. Simultaneously, we measured DXA fat distribution,
body weight, and total fat mass. Notably, our results show that
the mice supplemented with a HFD have a higher body
weight, fat mass, and distribution of high density fat compared
to mice fed a normal diet. When we compared GCBE and
HFD treatment groups, the GCBE group displayed a
signiﬁcant reduction of fat distribution and concentration, with
less body weight and fat mass.
In conclusion, this study shows GCBE treatment markedly
ameliorated body fat accumulation in HFD induced obesity and
reduced body weight gain, fat mass, adipocyte sizes, WAT
weight, and plasma lipid levels. We conﬁrm that the active
compound 3-CQA from GCBE, reduces body fat accumulation
by the regulation of adipogenesis and lipogenesis in obesity.
Thus, these ﬁndings demonstrate that GCBE represents a po-
tential activity that prevents the development of obesity,
hyperlipidemia and its complications in diseases.
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